Clinical value of combined detection of LDH, TPS, CEA and beta2-MG in patients with non- Hodgkin's lymphoma.
- Author:
Wei CHEN
1
;
Rong-cheng LUO
;
Wei-wen FAN
;
Shu-dong MA
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Biomarkers, Tumor; blood; Carcinoembryonic Antigen; blood; Female; Humans; L-Lactate Dehydrogenase; blood; Lymphoma, Non-Hodgkin; blood; diagnosis; Male; Middle Aged; Peptides; blood; Predictive Value of Tests; beta 2-Microglobulin; blood
- From: Journal of Southern Medical University 2006;26(2):227-230
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo study the clinical value of combined detection of 4 tumor markers, namely lactic dehydrogenate (LDH), tissue polypeptide specific antigen (TPS), carcinoembryonic antigen (CEA) and beta2-microglobulin (beta2-MG) in patients with non-Hodgkin's lymphoma (NHL).
METHODSThe serum level of LDH was determined with automatic biochemical analyzer and TPS, CEA and beta2-MG levels were determined by enzyme-linked immumosorbent assay (ELISA) in 59 patients with NHL and 40 healthy adults.
RESULTSThe levels of the 4 tumor markers were significantly higher in NHL patients than in the healthy control subjects (P<0.05). After chemotherapy, the serum levels of TPS and beta2-MG were significantly lowered in the patients who showed favorable response to the treatment (P<0.05), but the levels of LDH and CEA showed no significant change (P>0.05). The serum levels of LDH, TPS, CEA and beta2-MG in the patients in a stable or progressive phase did had no significant changes after chemotherapy (P>0.05).
CONCLUSIONCombined detection of LDH, TPS, CEA and beta2-MG can be helpful to assist diagnosis of NHL and treatment evaluation.
